葵花药业(002737) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥910,027,853.40, a decrease of 24.96% compared to ¥1,212,749,716.64 in the same period last year[10] - Net profit attributable to shareholders was ¥154,143,953.63, down 5.46% from ¥163,053,433.01 year-on-year[10] - The net profit after deducting non-recurring gains and losses was ¥146,023,980.47, a decrease of 5.98% compared to ¥155,304,348.18 in the previous year[10] - Basic earnings per share were ¥0.26, down 7.14% from ¥0.28 in the same period last year[10] - The weighted average return on net assets was 4.67%, a decrease of 0.19% compared to 4.86% in the previous year[10] - The total sales expenses for the first quarter were CNY 221,472,557.56, a decrease of 38.14% compared to the previous year due to the impact of the COVID-19 pandemic[23] - The company reported a significant increase in other operating expenses, which rose by 1404.90% to CNY 1,062,291.97, largely due to donations made in response to the COVID-19 pandemic[23] - The total profit for the first quarter was 204,058,184.40, down from 219,299,564.72, which is a decrease of approximately 6.5%[80] - The total comprehensive income for the first quarter was 161,211,841.39, down from 177,938,631.59, reflecting a decrease of about 9.48%[83] Cash Flow - The net cash flow from operating activities increased by 39.53% to ¥247,958,852.87 from ¥177,715,583.96 in the same period last year[10] - Cash inflow from operating activities totaled 1,003,722,549.28, down from 1,270,327,838.43 in the previous period, representing a decrease of approximately 21%[91] - The company reported a decrease in cash flow from operating activities due to a reduction in cash received from sales, which was 975,638,412.97 compared to 1,226,437,711.99 in the previous period[91] - Cash flow from investing activities showed a net outflow of -33,000,201.32, improving from -146,709,461.04 in the previous period[94] - Cash flow from financing activities resulted in a net inflow of 18,443,850.63, a significant decrease from 356,593,580.00 in the previous period[97] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,382,028,706.19, an increase of 1.37% from ¥5,309,290,285.34 at the end of the previous year[10] - The total liabilities decreased to CNY 1,781,254,807.75 from CNY 1,879,642,335.60, reflecting a reduction of about 5.2%[66] - The total equity attributable to shareholders increased to CNY 3,386,068,343.78 from CNY 3,224,119,367.21, representing an increase of approximately 5%[66] - The company's short-term borrowings rose to CNY 310,000,000.00 from CNY 300,000,000.00, reflecting an increase in debt[60] - The company's inventory decreased to CNY 578,961,524.83 from CNY 664,545,055.70, indicating a reduction in stock levels[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 47,531[14] - The company repurchased 1,575,157 shares at an average price below CNY 22 per share, totaling CNY 22.76 million, which is 0.27% of the total share capital[27] Regulatory Compliance and Commitments - The company has disclosed compliance with relevant laws and regulations regarding significant matters during the reporting period[23] - The company committed to repurchase all newly issued shares within five trading days if the prospectus contains false statements or omissions, with the repurchase price not lower than the public offering price plus interest[30] - The company will actively take legal measures to fulfill its commitments regarding the issuance and listing of shares, accepting supervision from regulatory authorities and investors[36] - The company has confirmed that all commitments have been fulfilled on time[36] Financial Management - The initial investment cost for securities investment in Guiyang Bank was CNY 93,600, with a current fair value of CNY 999,648, resulting in a report period profit of CNY 253,094[37] - The company has a total of CNY 20,500 in entrusted financial management, all sourced from idle self-owned funds[41] - The annualized return rate for the entrusted financial management product is 4.00%[41] Other Financial Metrics - The company reported a tax expense of 43,056,152.61, which is slightly higher than 41,210,039.74 from the previous year, representing an increase of about 4.48%[80] - The company recorded a financial expense of -1,286,871.13, compared to -5,535,347.32 in the previous year, indicating an improvement in financial costs[80]